Introduction {#Sec1}
============

Breast cancer is the most commonly diagnosed malignancy, accounting for 1 in 4 cancer cases among women worldwide^[@CR1],[@CR2]^. Treatment for breast cancer has improved, such that early treatment of breast cancer is associated with a good survival rate^[@CR3]^. It is important to identify women who have a higher risk of breast cancer to ensure that they can take necessary precautionary measures.

Mastitis refers to breast inflammation, comprising lactational and non-lactational mastitis. Lactational mastitis constitutes acute inflammation of the breast in connection with pregnancy or breastfeeding, and it occurs in 2--10% of breastfeeding women^[@CR4]^. Non-lactational mastitis is a breast inflammatory condition in non-breastfeeding women. The two major entities of non-lactational mastitis are periductal mastitis and idiopathic granulomatous mastitis and both of them primarily affect young women^[@CR5]--[@CR8]^.

Little is known regarding the risk of breast cancer in women with non-lactational mastitis. Owing to many studies supporting strong associations between chronic inflammatory conditions and tumorigenesis, a link between inflammation and cancer has been recognized^[@CR9]--[@CR11]^. Consequently, various infectious and inflammatory diseases are strongly associated with a high risk of malignancy in the corresponding organs^[@CR12]--[@CR15]^. However, whether or not women with non-lactational mastitis, as opposed to those without non-lactational mastitis, have a higher risk of breast cancer remains unknown. Therefore, the aim of this population-based cohort study was to examine the breast cancer risk in women with non-lactational mastitis using a national database of Taiwan. We also evaluated the risk of breast cancer among women with different numbers of episodes of non-lactational mastitis.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

Taiwan National Health Insurance (NHI) provides universal insurance coverage and is a single-payer system with the government as the sole insurer. It covers more than 99% of the Taiwanese population of 23.4 million people and has contracts with 97% of hospitals and clinics in Taiwan. Data regarding registration files and medical claims for all beneficiaries are linked through encrypted identification numbers in the National Health Insurance Research Database (NHIRD) (<http://nhird.nhri.org.tw/en/index.htm>). All diagnoses in the database are coded in accordance with the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM).

The National Health Research Institute of Taiwan has randomly selected 1 million NHI beneficiaries to establish a longitudinal database. No statistically significant differences in age, sex and health expenditure were found between the 1 million individuals in the longitudinal database and all NHI beneficiaries. This data set of 1 million randomly selected people was used in this study.

The Research Ethics Committee of China Medical University and Hospital in Taiwan approved the study (IRB permit number: CMUH-104-REC2-115-R3). Because we used the encrypted NHIRD dataset, the IRB determined that informed consent was not needed. Our research was performed in accordance with relevant guidelines and regulations.

Study population and design {#Sec4}
---------------------------

Lactational mastitis in the current study was defined as mastitis that occurred in women within 1 year of giving birth to a baby. Non-lactational mastitis was defined as mastitis that occurred in women beyond 1 year after giving birth to a baby, or in women who had never given birth to a baby.

Figure [1](#Fig1){ref-type="fig"} shows a flowchart of the method used to generate the non-lactational mastitis and comparison cohorts. First, we used ICD-9 codes (ICD-9: 611.0 and 675) to identify the mastitis group: women in the NHIRD who were newly diagnosed with mastitis or abscess between 2000 and 2011. Women who had at least two outpatient visits or one hospitalisation due to mastitis or abscess were included. The first date of mastitis diagnosis was established as the index date. To generate the non-lactational mastitis cohort, we excluded women with the following characteristics from the mastitis group: women who had lactational mastitis, women who had any pre-existing cancer before the index date, women who had any cancer including breast cancer within 1 year after the index date, women who did not have basic demographic information, women less than 20 years of age and men (Fig. [1](#Fig1){ref-type="fig"}, exclusion criteria). Exclusions were made for the following reasons: pre-existing cancer may become a competing mortality risk before the development of breast cancer; therefore, we excluded women who had previous histories of other cancers before the diagnosis of mastitis. In addition, we excluded women with breast cancer diagnosed within 1 year after the index date to avoid misdiagnosis of inflammatory breast cancer. The comparison group included women without any mastitis diagnosis, and the same exclusion criteria were applied. To avoid the influence of baseline differences in terms of age, index year, socioeconomic status (SES) and comorbidities, we performed 1:4 propensity score matching. The two groups were followed up from the index date until the occurrence of breast cancer, withdrawal from the database, or until 31 December 2013.Figure 1Flowchart for identifying women with non-lactational mastitis and the comparison group within the National Health Insurance Research Database.

Comorbidities and hormonal medications were identified using ICD-9 codes from the NHIRD. Comorbidities that have been reported as potential risk factors for breast cancer include schizophrenia^[@CR16]^, hypertension^[@CR17]^, chronic obstructive pulmonary disease^[@CR18]^, thyroid disease^[@CR19],[@CR20]^, diabetes^[@CR21]^, hyperlipidaemia^[@CR22]^ and obesity^[@CR23]^.

We used income-related insurance payment amounts as a proxy measure of individual SES. The SES was classified into four groups: (1) lower than US\$528/month (equivalent to NT\$15,840/month); (2) between US\$528 and US\$960/month (NT\$15,841 to NT\$28,800/month); (3) between US\$960 and US\$1526/month (NT\$28,801 to NT\$45,800/month); (4) greater than US\$1526/month (NT\$45,800/month). We selected US\$528/month (NT\$15,840/month) as the lowest income level for the SES cut-off point because this was the government-stipulated minimum wage for a full-time employee in Taiwan.

If a woman had more than one occurrence of non-lactational mastitis and the treatment interval was longer than 3 months, the second occurrence was defined as new non-lactational mastitis. We measured the occurrence of non-lactational mastitis per year among women in non-lactational mastitis cohort. We divided this occurrence data into three tertiles and analysed the risk of breast cancer.

We used the same procedure, excluding women with non-lactational mastitis, to generate the lactational mastitis cohort and analysed the breast cancer risk of women with lactational mastitis (Supplementary).

Statistical analysis {#Sec5}
--------------------

Four control women were matched to each woman with non-lactational mastitis who had a similar propensity score, based on nearest neighbour matching without replacement using calliper width within 0.1^[@CR24]^. Differences in each variable in the non-lactational mastitis and comparison cohorts were calculated by using the standardised mean difference (SMD)^[@CR25],[@CR26]^; an SMD of \<0.1 was considered to indicate a negligible difference^[@CR25]^. We described the grouped age, comorbidities and medications in the two cohorts as numbers and percentages; we presented the mean ages as means and standard deviations.

To estimate the risk of breast cancer in the non-lactational mastitis and comparison cohorts, hazard ratios (HRs), adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were evaluated by using crude and adjusted Cox proportional hazard models, respectively. All statistical analyses were performed using SAS statistical software, version 9.4 (SAS Institute Inc., Cary, NC, USA). The figure for the cumulative incidence curve was plotted by R software. Significance was indicated by a two-sided p-value of \<0.05.

Results {#Sec6}
=======

A total of 3,091 women with non-lactational mastitis were enrolled in this study (Table [1](#Tab1){ref-type="table"}). The mean age of the women with non-lactational mastitis was 37.9 years; most (64%) were \<40 years of age. After matching by age, SES and comorbidities, the SMDs between the non-lactational mastitis and comparison groups did not significantly differ (SMD \<0.1), with the exception of the rate (%) of hormonal medication, which was higher in the non-lactational mastitis group than in the comparison group (SMD = 0.35).Table 1Demographic characteristics of the non-lactational mastitis women and the comparison group.TotalComparisonNon-lactational MastitisStandardized mean difference^§^n = 15455n = 12364n = 3091nn (%)/mean (SD)n (%)/mean (SD)Age at baseline^‡^37.7 (12.5)37.9 (11.9)0.021\<4097487767 (62.8)1981 (64.1)0.02640--4932682640 (21.4)628 (20.3)0.02550--5915591246 (10.1)313 (10.1)0.002≥60880711 (5.8)169 (5.5)0.012**Monthly income (NT\$)**0--1584085636856 (55.5)1707 (55.2)0.00515841--2880050844068 (32.9)1016 (32.9)0.00128801--4580013891111 (9)278 (9)0.000\>45800419329 (2.7)90 (2.9)0.015**Baseline comorbidity**Schizophrenia388310 (2.5)78 (2.5)0.001Hypertension17671381 (11.2)386 (12.5)0.041Chronic obstructive pulmonary disease17801408 (11.4)372 (12)0.020Thyroid disease13521064 (8.6)288 (9.3)0.025Diabetes1233978 (7.9)255 (8.2)0.012Hyperlipidemia19361532 (12.4)404 (13.1)0.020Obesity201158 (1.3)43 (1.4)0.010**Medication**Hormonal medication82786192 (50.1)2086 (67.5)0.359Abbreviation: SD, standard deviation.^‡^Student's t test.^§^A standardized mean difference of \<0.1 indicates a negligible difference between the two cohorts.

Table [2](#Tab2){ref-type="table"} shows the events, HRs and risk factors of breast cancer. There were a total of 111 cases of newly diagnosed breast cancer. Women with non-lactational mastitis had a significantly higher risk of breast cancer (aHR = 1.94, 95% CI: 1.30--2.90). Age was also an important risk factor for breast cancer: women aged 40--49 years (aHR = 2.60, 95% CI: 1.63--4.14), 50--59 (aHR = 2.67, 95% CI: 1.43--4.96) and women aged \>60 years (aHR = 2.66, 95% CI: 1.41--6.21) had higher risks of breast cancer than women aged \<40 years.Table 2Cox proportional hazards regression measured hazard ratio of breast cancer.EventCrudeAdjusted(n = 111)HR (95% CI)p-valueHR (95% CI)p-value**Non-lactational mastitis**No74Ref.Ref.Yes371.94 (1.31--2.87)0.0011.94 (1.30--2.90)0.001**Age at baseline**\<4042Ref.Ref.40--49422.96 (1.93--4.54)\<0.0012.60 (1.63--4.14)\<0.00150--59183.04 (1.75--5.28)\<0.0012.67 (1.43--4.96)0.002≥6092.92 (1.42--6.01)0.0042.66 (1.14--6.21)0.023**Monthly income (NT\$)**0--1584038Ref.Ref.15841--28800522.01 (1.32--3.05)0.0011.42 (0.91--2.22)0.12728801--45800142.02 (1.09--3.72)0.0251.34 (0.71--2.55)0.370\>4580073.41 (1.52--7.63)0.0032.41 (1.05--5.53)0.038**Baseline comorbidity**Schizophrenia62.46 (1.08--5.6)0.0322.66 (1.16--6.09)0.021Hypertension181.68 (1.02--2.79)0.0440.91 (0.5--1.67)0.773Chronic obstructive pulmonary disease161.54 (0.91--2.63)0.1081.15 (0.66--2.00)0.611Thyroid disease60.71 (0.31--1.62)0.4160.58 (0.25--1.32)0.194Diabetes131.75 (0.98--3.12)0.0591.19 (0.61--2.32)0.611Hyperlipidemia191.64 (1--2.68)0.0510.98 (0.54--1.77)0.939Obesity0------**Medication**Hormonal medication561.06 (0.73--1.55)0.7451.00 (0.68--1.48)0.982\*Abbreviation: HR, hazard ratio; CI, confidence interval.\*Adjusted HR: adjusted for age, income, comorbidities and medication in Cox proportional hazards regression.

Figure [2](#Fig2){ref-type="fig"} demonstrates that the cumulative incidence of breast cancer in women with non-lactational mastitis was higher than in the comparison group (p \< 0.001). Table [3](#Tab3){ref-type="table"} presents the risk developing of breast cancer by incidence rate (IR) and HR after stratification by age, sex, comorbidities and hormonal medication. The overall IRs of breast cancer in the non-lactational mastitis and comparison groups were 14.79 and 7.57 per 10,000 person-years, respectively. Compared with women in the comparison group, women who had non-lactational mastitis before the age of 40 years (aHR = 2.22, 95% CI: 1.18--4.18) and at the age of 40 to 49 years of age (aHR = 2.00, 95% CI: 1.11--4.04) had a significantly higher risk of breast cancer. Non-lactational mastitis was a risk factor for breast cancer in women with lower SES (monthly income \<USD\$528, aHR = 2.60, 95% CI: 1.34--5.07) and in women who ever took hormonal medication (aHR = 1.96, 95% CI: 1.15--3.34). However, women with lactational mastitis did not exhibit a statistically significant risk of developing breast cancer, relative to women in the comparison group (Supplementary Tables [S1](#MOESM1){ref-type="media"}--[S3](#MOESM1){ref-type="media"}).Figure 2The cumulative incidences of breast cancer in women with non-lactational mastitis and the comparison group.Table 3Incidence rate, hazard ratio of breast cancer in different stratification.ComparisonNon-lactational mastitisNon-lactational mastitis vs Comparisonn = 12364n = 3091Crude HRAdjusted HREventPerson yearsIREventPerson yearsIR(95% CI)(95% CI)Overall74977227.57372501014.791.94 (1.31--2.87)\*\*1.94 (1.30--2.90)\*\***Age at baseline**\<4026624394.1616161689.902.36 (1.27--4.4)\*\*2.22 (1.18--4.18)\*40--49282129413.1514524526.692.00 (1.05--3.81)\*2.12 (1.11--4.04)\*50--5914906115.454245416.301.03 (0.34--3.12)1.28 (0.41--4.02)≥606492812.183114326.252.21 (0.55--8.84)1.80 (0.43--7.48)**Monthly income (NT\$)**0--1584023519754.43151295211.582.63 (1.37--5.04)\*\*2.60 (1.34--5.07)\*\*15841--28800363394610.6116888618.011.66 (0.92--3.00)1.68 (0.93--3.06)28801--45800991259.865242020.672.05 (0.69--6.12)2.02 (0.66--6.16)\>458006267622.42175313.290.59 (0.07--4.86)0.53 (0.06--4.99)**Baseline comorbidity**Schizophrenia5222722.46162216.070.67 (0.08--5.76)0.84 (0.09--7.60)Hypertension12998812.016299720.021.60 (0.60--4.27)1.63 (0.60--4.42)Chronic obstructive pulmonary disease11986111.165276618.071.61 (0.56--4.65)1.39 (0.47--4.05)Thyroid disease574146.74121444.660.67 (0.08--5.72)0.61 (0.07--5.47)Diabetes10702314.243191315.681.08 (0.30--3.91)1.05 (0.28--3.85)Hyperlipidemia141108912.635309916.131.24 (0.45--3.46)1.16 (0.41--3.25)Obesity010640.0003200.00------**Medication**Hormonal medication33454237.27231614314.251.93 (1.13--3.28)\*1.96 (1.15--3.34)\*\*Abbreviation: IR, incidence rates, per 10,000 person-years; HR, hazard ratio; CI, confidence interval.\*Adjusted HR: adjusted for age, income, comorbidities and medication in Cox proportional hazards regression.*\*p-*value \< 0.05 \**p-*value \< 0.01\*\*.

Table [4](#Tab4){ref-type="table"} shows that the number of episodes of non-lactational mastitis affected the risk of breast cancer; most breast cancer cases were in the third tertile. There was a trend that the risk increased as the occurrence of non-lactational mastitis increased. The IR was 36.54 per 10,000 person-years (aHR = 5.50, 95% CI: 3.31--9.13) in the third tertile, compared to 7.57 per 10,000 person-years in the comparison group. The average time for development of breast cancer after the diagnosis of non-lactational mastitis was 6.03 years. The average numbers of episodes of non-lactational mastitis per year for women with and without breast cancer were 0.51 and 0.26, respectively (p = 0.005).Table 4Incidence rate and hazard ratio of breast cancer by the episode of non-lactational mastitis.Non-lactational mastitis episode (mean per year)EventPYIRCrude HR (95% CI)p-valueAdjusted HR (95% CI)p-valueComparison group (0)74977227.57Ref.Ref.First tertile (\<0.14)6107325.590.68 (0.30--1.56)0.360.69 (0.30--1.58)0.38Second tertile (0.14--0.27)11880512.491.61 (0.86--3.04)0.141.68 (0.89--3.19)0.11Third tertile (\>0.27)20547336.545.77 (3.50--9.53)\<0.0015.50 (3.31--9.13)\<0.001\*Abbreviation: PY, person-years; IR, incidence rate, per 100,000 person-years; HR, hazard ratio; CI, confidence interval.\*Adjusted HR: adjusted for age, income, comorbidities and medication in Cox proportional hazards regression.

Discussion {#Sec7}
==========

In this population-based study, we found that non-lactational mastitis occurred mostly in young women in Taiwan. Women who had non-lactational mastitis had a significantly higher risk of developing breast cancer than women who did not. Non-lactational mastitis was a risk factor of breast cancer among these three subgroups: women aged \<50 years, women with lower socioeconomic status and women with hormonal medication. In addition, women who had more episodes of non-lactational mastitis had an increased risk of breast cancer development.

Consistent with the literature^[@CR27],[@CR28]^, our findings demonstrated that middle aged and old aged women had higher risks of breast cancer than women aged \<40 years (Table [2](#Tab2){ref-type="table"}). In stratified analysis, there was a significantly increased risk of breast cancer in women with non-lactational mastitis aged \<50. Women with non-lactational mastitis aged ≥50 years were also associated with an increased risk of breast cancer; however, this association was not statistically significant. This is potentially because non-lactational mastitis occurred mostly in younger women in Taiwan. In addition, the small numbers of women with non-lactational mastitis aged ≥50 years may be the reason for the lack of significance.

It is known that there is a small increase in the risk of breast cancer diagnoses in women taking oral contraceptives, as well as up to 10 years after discontinuation of oral contraceptives^[@CR29]^. A higher percentage of women in our non-lactational mastitis group had a history of hormonal medication, relative to women in the comparison group; therefore, we stratified our analysis by hormonal medication history. Among women who had a history of hormonal medication, those who had non-lactational mastitis exhibited a significantly higher risk of breast cancer than those who did not have non-lactational mastitis. We could not attribute the increased risk of breast cancer in the women with non-lactational mastitis to hormonal medication.

Our results showed that the risk of breast cancer in women increased significantly as the occurrence of non-lactational mastitis increased. Non-lactational mastitis is known to be related to chronic inflammation secondary to infection-induced cytokines^[@CR30]^, as well as inflammatory, infectious, hormonal and autoimmunity factors^[@CR31],[@CR32]^. Reportedly, the presence of exogenous and endogenous pathogen-associated molecular patterns (PAMPs) (bacteria, viruses and fungi, as well as endogenous molecules released from injured or dying cells) can cause the activation of inflammatory pathways^[@CR33]^. Chronic inflammation is further compounded by potentially malignant transformation^[@CR33]--[@CR37]^. Repeated occurrence of non-lactational mastitis in women may indicate that they are in a status of long-term exposure to these PAMPs that damages their breast and drives their breast cancer risk higher. However, further studies are needed to reveal the association of non-lactational mastitis with breast cancer. Our findings may serve as an epidemiological support for population-based observations.

The strength of this study is that it was a nationwide, population-based study. The NHI covers 99% of Taiwan's population and has nearly complete medical records for the entire population. The results of this population-based cohort study are noteworthy, as non-lactational mastitis is not a very common disease, and the breast cancer incidence is approximately 188--194 per 100,000 women in Taiwan^[@CR38]^; individual studies have been unable to reveal an association between non-lactational mastitis and breast cancer in women because they have been limited by either small sample size or cross-sectional design.

There were some limitations in this study. First, ICD codes were used to determine the diagnosis of mastitis. However, there is not a specific code to identify the entity and aetiology of non-lactational mastitis in the ICD-9 coding system. Second, this study did not identify when women stopped breastfeeding after delivery of a baby. In the literature, the median duration of breastfeeding is reportedly 7--12 months^[@CR39],[@CR40]^. To reduce the misclassification of lactational mastitis as non-lactational mastitis, our cut-off for non-lactational mastitis was 1 year after giving birth to a baby. Third, residual and unmeasured confounding factors might exist; lifestyle-related variables (e.g. smoking and diet), family history and parity status are not recorded in the NHIRD. However, we were able to adjust for SES, comorbidities and hormonal medication, which are known risk factors for breast cancer. Finally, the follow-up period was short; however, the significance of non-lactational mastitis as a risk factor for breast cancer in the younger age group was dominant.

In summary, this study showed a significant risk of breast cancer in women with a history of non-lactational mastitis. Moreover, their risk of breast cancer was higher with increased frequency of non-lactational mastitis. The majority of the population in this study was in the younger age group (\<40 years), and the follow-up period was short; therefore, further studies should be performed in a population with a wider age range and a longer follow-up period.
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